Réda Chebani, Florian Lombart, Guillaume Chaby, Ali Dadban, Sébastien Debarbieux, Manuelle-Anne Viguier, Saskia Ingen-Housz-Oro, Anne Pham-Ledard, Christophe R Bedane, Catherine Picard-Dahan, Clémence Berthin, Olivier Dereure, Maria-Polina Konstantinou, Marion Castel, Fabienne Jouen, Pascal Joly, Vannina Seta, Sophie Duvert-Lehembre, Christelle Le Roux, Gaëlle Quereux, Bruno Sassolas, Emilie Brenaut, Carole Sin, Marie-Aleth Richard, Frédéric Bérard, Delphine Giusti, Thibaut Belmondo, Thomas Gille, Frédéric Caux, Catherine Prost-Squarcioni, Sabine Grootenboer-Mignot, Marina Alexandre
BACKGROUND: Interest in the use of omalizumab to treat bullous pemphigoid (BP) in the event of resistance or contraindication to conventional therapies is currently based on limited evidence. OBJECTIVES: To assess the effectiveness and safety of omalizumab in BP and to identify predictive factors in response to treatment. METHODS: We conducted a French national multicentre retrospective study including patients with a confirmed diagnosis of BP treated with omalizumab after failure of one or several treatment lines...
January 23, 2024: British Journal of Dermatology